News & Analysis as of

Investment Pharmaceutical Industry Investors

McDermott Will & Schulte

McDermott HealthEx 2025: McKinsey Key Takeaways

McDermott HealthEx convened more than 1,300 of the most influential leaders in healthcare and life sciences. The event emphasized creativity, transformation, and growth, with sessions dedicated to innovation, AI-powered...more

McGuireWoods LLP

Insights From the 21st Annual McGuireWoods Healthcare Private Equity and Finance Conference: Part 1

McGuireWoods LLP on

McGuireWoods held its 21st Annual Healthcare Private Equity and Finance Conference in Chicago, May 13-15, 2025. This premier conference brought together leading healthcare investors, lenders, executives, consultants and...more

McDermott Will & Schulte

Investment Opportunities in TechBio and Pharma Services - European Health & Life Sciences Symposium 2025

In April 2025, McDermott once again hosted its annual European Health & Life Sciences Symposium at the Shangri-La hotel in Paris. Attended by some 300 delegates from across the industry, participants including investors,...more

McDermott Will & Schulte

Transaction and Financing Trends in Life Sciences - European Health & Life Sciences Symposium 2025

In April, McDermott was pleased to once again host our annual European Health & Life Sciences Symposium in Paris. Welcoming a crowd of more than 300 innovators, investors, business leaders and advisers from across the...more

McDermott Will & Schulte

European Health & Life Sciences Symposium 2025: Key Takeaways

In April 2025, we were proud to host the annual European Health & Life Sciences Symposium at the Shangri-La hotel in Paris. Attended by some 300 delegates from across the industry, participants including investors,...more

Ropes & Gray LLP

Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025

Ropes & Gray LLP on

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw a resurgence, signaling renewed investor confidence and reflecting sustained...more

Foley & Lardner LLP

Drilling Down into Venture Capital Financing in Artificial Intelligence

Foley & Lardner LLP on

It should come as no surprise that venture capital (VC) investors are drilling down into startups building businesses with Artificial Intelligence (AI) at the core. New data from PitchBook actually shows that AI startups make...more

Bradley Arant Boult Cummings LLP

How Will the Cannabis World Look When Marijuana Is Rescheduled?

A few weeks ago, someone at a holiday party asked “Whitt, why doesn’t Budding Trends take on the weighty legal issues of the day and instead resort to cheap pop culture references and puns?” I thought about responding with a...more

Goodwin

The 43rd Annual J.P. Morgan Healthcare Conference Starts Today - A Who’s Who in Biologics at this Year’s Conference

Goodwin on

The JP Morgan Healthcare Conference (“JPM”) “is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology...more

McDermott Will & Schulte

Key Takeaways | State of the Market – Still Looking for an Exit

During this session, the panelists discussed notable developments within the life sciences industry with a specific focus on the GLP-1 drug market and its opportunities for improvement in patient satisfaction and dosage. They...more

Ropes & Gray LLP

[Podcast] Health Care Transaction Laws Unwrapped: Recent Developments on the West Coast

Ropes & Gray LLP on

On this fourth episode of Ropes & Gray’s Health Care Transaction Laws Unwrapped podcast series, health care attorneys Ranee Adipat, Jenn Romig and Jaclyn Freshman discuss the latest updates to state health care transaction...more

McDermott Will & Schulte

HPE Europe 2024: Key Takeaways

On 19 September 2024, we were once again delighted to assemble hundreds of healthcare professionals, investors, and industry changemakers at The Langham  in London for our annual Healthcare Private Equity (HPE) Europe...more

A&O Shearman

Key takeaways from the LSX World Congress USA

A&O Shearman on

On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector....more

Blake, Cassels & Graydon LLP

Key Tips for Building a Successful Life Sciences Company

Starting a company in the life sciences sector comes with its unique set of challenges and learning opportunities. From establishing a solid foundation built on a strong business case and clear legal documentation to...more

Bass, Berry & Sims PLC

Healthcare Trends & Transactions Q2 2024

Bass, Berry & Sims PLC on

Deal volume across the healthcare industry generally appears to have steadied despite headwinds. The general sentiment is that buyers have adapted to the current interest rates and are gritting their teeth and pressing...more

McDermott Will & Schulte

Key Takeaways | Contract Research Organizations (CROs)

During this session, the panelists discussed the current market outlook for CROs and the key differentiators making them attractive to private equity investors, such as therapeutic area (TA) specialization, their ability to...more

Bass, Berry & Sims PLC

Key Takeaways from 2024 Asembia Specialty Pharmacy Summit

Bass, Berry & Sims PLC on

Asembia’s 20th Annual Specialty Pharmacy Summit once again brought investors and operators in the specialty pharmacy ecosystem to Las Vegas for learning sessions and networking. Bass, Berry & Sims brought a team of four...more

Mintz

Doing Life Sciences Deals in 2024

Mintz on

Nearly one hundred life sciences professionals convened at Mintz’s Boston office last week for an event we hosted in partnership with the LES (Licensing Executives Society). I moderated a panel, “Structuring Your Life...more

White & Case LLP

Oncology dealmaking fuels biotech M&A

White & Case LLP on

Global spending on cancer medicines is set to reach US$375 billion by 2027, with innovation in drug discovery and development ramping up to meet rising demand. While the global biotech sector continues to grapple with...more

Fenwick & West Life Sciences Group

In 2024, the Digital Health Revolution Continues

Digital health is showing signs of life despite financial markets that seem determined to bring some of 2023’s volatility into the new year. Stocks are up and down, and bond yields are climbing. Inflation is proving stubborn,...more

Bass, Berry & Sims PLC

2024 Healthcare Private Equity Outlook & Trends

W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity. As we begin 2024, we have highlighted the issues and trends that...more

A&O Shearman

Global M&A Insights: Deal-making predictions for 2024

A&O Shearman on

Welcome to our year-end edition of M&A Insights, where we preview some of the themes we expect to shape deal-making over the next 12 months. Continued volatility in the debt markets has resulted in another subdued year for...more

McDermott Will & Schulte

European Health & Life Sciences Symposium 2023 | Key Takeaways

McDermott Will & Schulte on

200+ leading individuals in healthcare, life sciences and private equity gathered at the Shangri-La Hotel in Paris for the European Health & Life Sciences Symposium 2023 to enjoy a day packed with fireside chats, in-depth...more

Latham & Watkins LLP

Side Effects for PE Amid Changing EU Life Sciences and Healthcare Landscape

Latham & Watkins LLP on

Substantial changes to the European life sciences and healthcare regulatory landscape are expected to reshape the sector. EU regulators have outlined a raft of reforms to modernise regulatory architecture, simplify product...more

McGuireWoods LLP

Private Equity in Healthcare – An Updated Review of Selected Niche Investment Areas

McGuireWoods LLP on

Since mid-2022, the macro acquisition environment has faced the challenges of inflation and increasing interest rates, among a variety of other headwinds. Global deal flow is down from its 2021 peak. Yet, as this white paper...more

50 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide